ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

KOOL Cesca Therapeutics Inc

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Cesca Therapeutics Inc NASDAQ:KOOL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

24/10/2019 1:30pm

PR Newswire (US)


Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Cesca Therapeutics Charts.

RANCHO CORDOVA, Calif., Oct. 24, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET.  

Management will also be available for one-on-one meetings with qualified investors.  Interested parties can register and request meetings through the Dawson James conference portal or contact Rx Communications to schedule a meeting.

A live webcast of the presentation will be available on Cesca Therapeutics' website at http://investors.cescatherapeutics.com/events-and-presentations/events. An archived replay will be available for a period of 90 days after the conference.

About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed a semi- automated, functionally closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca and ThermoGenesis, please visit: www.cescatherapeutics.com.

Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

Cision View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-dawson-james-securities-5th-annual-small-cap-growth-conference-300943746.html

SOURCE Cesca Therapeutics Inc.

Copyright 2019 PR Newswire

1 Year Cesca Therapeutics Chart

1 Year Cesca Therapeutics Chart

1 Month Cesca Therapeutics Chart

1 Month Cesca Therapeutics Chart